U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880042) titled 'COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO' on March 11.
Brief Summary: Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed
Study Start Date: March 11
Study Type: INTERVENTIONAL
Condition:
Vitiligo - Macular Depigmentation
Tacrolimus
Intervention:
DRUG: Tacrolimus
Tacrolimus is calcineurin inhibitor that will act as immunomodulator
DRUG: Calcipotriol
Calcipotriol is a vitami...